HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias - Top-Institutions - MDSpire

HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias

  • By

  • Rony Mshaik

  • John Simonet

  • Aleksandra Georgievski

  • Layla Jamal

  • Shaliha Bechoua

  • Paola Ballerini

  • Pierre-Simon Bellaye

  • Zandile Mlamla

  • Jean-Paul Pais de Barros

  • Audrey Geissler

  • Pierre-Jean Francin

  • François Girodon

  • Carmen Garrido

  • Ronan Quéré

  • March 18, 2021

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Molecular Therapeutics

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Experimental Therapeutics

  • #3

    St. Jude Children's Research Hospital
    St. Jude Children's Research Hospital

    Memphis, TN

    Key Differentiators

    • Pediatric Oncology
    • Hematology
    • Molecular Biology

  • #4

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology
    • Oncology
    • Translational Research

Original Source(s)

HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias

  • by Rony Mshaik, John Simonet, Aleksandra Georgievski, Layla Jamal, Shaliha Bechoua, Paola Ballerini, Pierre-Simon Bellaye, Zandile Mlamla, Jean-Paul Pais de Barros, Audrey Geissler, Pierre-Jean Francin, François Girodon, Carmen Garrido, Ronan Quéré

  • March 18, 2021

Related Content